The 50% hemolysis (CH50) immunological test is a functional complement assay that quantifies the total hemolytic activity of the classical complement pathway in serum. As a core laboratory tool for evaluating immune complex diseases, complement deficiencies, and autoimmune disease activity, CH50 testing is widely performed in clinical immunology laboratories and accredited third-party diagnostic laboratories. This article explains the analytical principle, sample requirements, testing items, methodologies, clinical applications, and frequently asked questions related to the CH50 complement hemolytic assay.
Technical Overview
The 50% hemolysis test, commonly designated CH50 (also written CH-50 or CH100 in some laboratory systems), is a quantitative immunological assay that measures the functional integrity of the complete classical complement cascade in serum. The complement system consists of more than 30 plasma and cell-surface proteins that mediate opsonization, inflammation, and complement-dependent cytotoxicity. Because effective hemolysis requires every classical pathway component (C1 through C9) to be present and active, the CH50 assay serves as a global screen for complement function, capable of detecting both inherited and acquired deficiencies of any single component in the pathway.
The analytical principle is based on complement-mediated lysis of antibody-sensitized sheep erythrocytes (EA cells). Sheep red blood cells coated with rabbit anti-sheep erythrocyte hemolysin form antigen-antibody complexes that activate C1q, triggering the sequential cascade of C4, C2, C3, C5, C6, C7, C8, and C9, culminating in assembly of the membrane attack complex (MAC) and osmotic lysis of the erythrocytes. Released hemoglobin is measured spectrophotometrically at approximately 541 nm, the absorption maximum of oxyhemoglobin.
The degree of hemolysis follows a sigmoidal dose-response curve when plotted against the logarithm of serum concentration. According to the Von Krogh relationship, the curve is steepest at the 50% hemolysis endpoint, where measurement precision is maximized. Consequently, the assay result is expressed as the reciprocal of the serum dilution that produces 50% lysis of a standardized erythrocyte suspension, reported in complement hemolytic units per milliliter (U/mL). Testing is typically performed in clinical laboratories operating under quality frameworks such as ISO 15189, with method validation aligned to recognized clinical laboratory standards.
Testing Samples
Serum
Serum is the standard specimen for CH50 determination. A venous blood sample is collected into a plain tube without anticoagulant, allowed to clot completely, and centrifuged to obtain clear serum. The required volume is typically 1–2 mL of serum, although microplate adaptations can reduce the minimum volume considerably.
Sample Collection and Handling Requirements
Complement proteins are thermolabile and are rapidly consumed in vitro, so specimen handling is critical to result validity:
- Process and separate the blood sample within one hour of collection to prevent post-phlebotomy complement activation.
- Test fresh serum immediately whenever possible, or store at 2–8 °C for a maximum of a few hours.
- For longer storage, freeze serum at −70 °C or below in aliquots to avoid repeated freeze-thaw cycles that degrade complement activity.
- Samples containing cryoglobulins should be kept warm (37 °C) during transport and clotting to prevent cold-activated complement consumption.
- Label specimens clearly and accompany them with relevant clinical information such as suspected immune complex disease or complement deficiency.
Specimens Considered Unsuitable
Plasma anticoagulated with EDTA or citrate is generally unsuitable for functional CH50 assays because chelation of calcium and magnesium ions blocks the classical pathway activation required for hemolysis. Markedly hemolyzed specimens are rejected because endogenous free hemoglobin interferes with the spectrophotometric measurement of hemoglobin release. Grossly lipemic or icteric samples may also cause optical interference and require caution or recollection.
Testing Items
The 50% hemolysis immunological panel encompasses several analytically related determinations that together characterize complement system function:
- Total classical pathway hemolytic activity (CH50), expressed in U/mL, the primary test item.
- Alternative pathway hemolytic activity (AH50), performed with rabbit erythrocytes in magnesium-containing EGTA buffer to isolate the alternative pathway.
- Quantitative complement proteins C3 and C4, typically measured by immunoturbidimetry or nephelometry, to distinguish consumption from synthesis defects.
- C1 esterase inhibitor (C1-INH) functional and antigenic assays where hereditary angioedema is suspected.
- Complement activation products such as C3a, C5a, C4d, and soluble C5b-9 (SC5b-9), measured by immunoassay for activation-state assessment.
Typical adult reference intervals for CH50 fall in the range of approximately 30–60 U/mL, although exact limits must be established or verified by each laboratory for its specific method and population.
Testing Methods
Classical Mayer Tube and Microplate CH50 Method
The reference functional method follows the classical Mayer procedure, frequently adapted to 96-well microplate format for efficiency:
- Sheep erythrocytes are washed and standardized to a defined cell concentration, then sensitized with an optimized amount of rabbit anti-sheep hemolysin to prepare EA cells.
- Serial dilutions of patient serum, and of a control serum, are prepared in veronal-buffered saline containing gelatin with calcium and magnesium ions.
- EA cells are added to each dilution and incubated at 37 °C for 30–60 minutes to allow complement-dependent hemolysis.
- Reactions are centrifuged to pellet intact cells, and hemoglobin release in the supernatant is measured by absorbance at 541 nm against 100% lysis (water lysis control) and 0% lysis (buffer blank) controls.
- The percentage of hemolysis is plotted against the logarithm of serum dilution using the Von Krogh transformation, and the dilution producing exactly 50% hemolysis is interpolated.
- The CH50 value in U/mL equals the reciprocal of the 50% endpoint dilution multiplied by the dilution factor and serum volume correction factor.
Automated Liposome-Based Immunoassay
Modern clinical analyzers employ a liposome immunoassay principle in which liposomes encapsulating a reporter enzyme are sensitized with a hapten such as dinitrophenyl and coated with specific antibody. Complement in the patient sample is activated by the antigen-antibody complex on the liposome surface, generating the membrane attack complex, lysing the liposomes, and releasing the enzyme. The liberated enzyme activity, measured by a colorimetric substrate, is directly proportional to total complement activity. This approach offers automated throughput, improved reproducibility, and full traceability of calibration, making it suitable for high-volume clinical laboratories.
Complementary Immunoassays
Because functional hemolytic assays do not identify which individual component is deficient, CH50 testing is commonly reflexed with quantitative assays:
- Immunoturbidimetric or nephelometric quantification of C3 and C4 on clinical chemistry platforms.
- ELISA-based measurement of activation fragments (C3a, C5a, SC5b-9) for evaluating in vivo complement activation.
- Radial immunodiffusion or multiplex immunoassays for screening multiple complement components simultaneously.
Quality Control and Standardization
Each analytical run includes normal and abnormal control sera with assigned CH50 values, verification of erythrocyte standardization, and validation of the hemolysin sensitization optimum. Accredited laboratories follow internal quality control and external quality assessment programs consistent with ISO 15189 and ISO/IEC 17025 requirements, and reference measurement approaches traceable to international reference materials where available. Samples yielding values below the detection limit are reported as markedly decreased or undetectable, prompting repeat sampling and component-level testing to exclude hereditary deficiency.
Applications
CH50 immunological testing has broad diagnostic and monitoring value across clinical immunology, nephrology, rheumatology, and biopharmaceutical safety evaluation:
- Assessment of systemic lupus erythematosus disease activity, in which falling CH50 with depressed C3 and C4 indicates active immune complex formation and complement consumption.
- Evaluation of immune complex-mediated disorders including rheumatoid arthritis with vasculitis, mixed cryoglobulinemia, and serum sickness-like reactions.
- Investigation of glomerulonephritides, particularly post-infectious glomerulonephritis and membranoproliferative glomerulonephritis, where serial CH50 monitoring tracks disease evolution.
- Screening for hereditary complement component deficiencies presenting with recurrent neisserial infections, recurrent angioedema, or autoimmune-like syndromes.
- Differentiation of hypocomplementemia mechanisms: consumption versus reduced hepatic synthesis in advanced liver disease or protein-losing states, complement consumption in sepsis and disseminated intravascular coagulation, and cold agglutinin autoimmune hemolytic anemia.
- Pharmacotherapeutic monitoring of complement-inhibiting biologics, such as anti-C5 monoclonal antibody therapy, where CH50 suppression confirms effective pathway blockade.
- Biocompatibility and immunotoxicology testing programs for blood-contacting medical devices and pharmaceutical products, where complement activation is evaluated in accordance with ISO 10993-4 requirements by accredited third-party laboratories.
FAQ
What is the CH50 test and why is 50% hemolysis used as the endpoint?
The CH50 test measures the total functional activity of the classical complement pathway in serum. The 50% hemolysis endpoint is selected because the hemolysis-versus-serum-dilution curve is steepest at this point, giving the highest analytical sensitivity to small changes in complement concentration, as described by the Von Krogh equation.
What does a low CH50 result mean?
A decreased CH50 indicates reduced functional complement activity, which may result from activation and consumption in immune complex disease, glomerulonephritis, sepsis, cryoglobulinemia, or autoimmune hemolysis; from impaired synthesis in severe liver disease or malnutrition; or from hereditary deficiency of a classical pathway component. A persistently undetectable CH50 strongly suggests a homozygous component deficiency and warrants component-specific testing.
Can CH50 be elevated?
Yes. Increased CH50 values occur as an acute-phase response in inflammation, infection, trauma, myocardial infarction, malignancy, and pregnancy, reflecting increased complement protein synthesis. Elevated results are generally clinically supportive rather than diagnostic.
How should the sample be collected and transported?
Collect venous blood into a plain clot tube without anticoagulant, separate serum within one hour, and analyze promptly. If testing is delayed, freeze serum at −70 °C and ship frozen on dry ice. Avoid hemolysis, freeze-thaw cycles, and EDTA or citrate plasma, all of which invalidate the functional assay.
How does CH50 differ from C3 and C4 measurements?
CH50 is a functional assay that requires the entire classical pathway to be intact, whereas C3 and C4 are quantitative protein measurements. A normal CH50 with isolated low C4 may reflect a hereditary C4 deficiency or limited activation, while a low CH50 with low C3 and C4 indicates significant consumption. Combining both approaches provides the most complete complement evaluation.
What are the limitations of the CH50 assay?
The assay is insensitive to minor complement consumption because the reference interval is broad, it cannot identify the deficient component when CH50 is low, it is vulnerable to pre-analytical degradation from delayed processing or improper storage, and results may be uninterpretable in hemolyzed or lipemic specimens. These limitations are addressed through strict specimen handling and reflexive component testing.
What is the typical turnaround time?
Most clinical laboratories report CH50 results within 24 to 72 hours of sample receipt, with automated liposome-based methods offering same-day throughput. Complex follow-up testing, such as individual component assays or activation-product measurement, may require additional time depending on the test menu of the performing laboratory.